Destination: Personalized Disease Management Approaches for People with Autoimmune Diseases

Destination: Personalized Disease Management Approaches for People with Autoimmune Diseases

SPONSOR CONTENT BY BRISTOL-MYERS SQUIBB

Biomarkers may offer disease management “road maps” for autoimmune disease patients

Biomarkers may help physicians make predictions about autoimmune disease progression and serve as markers of therapeutic response, making them important tools in guiding personalized disease management approaches. One such biomarker, anti-citrullinated protein antibody (ACPA), is common in rheumatoid arthritis, and linked with poor prognosis. Data examining the implications of ACPA positivity on rheumatoid arthritis outcomes and costs are among new autoimmune disease insights Bristol-Myers Squibb is presenting at the 2018 ACR/ARHP Annual Meeting. Learn more.